Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jul 10 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Diroximel Fumarate Delayed-Release Capsules. This medication is intended for the treatment of relapsing forms of multiple sclerosis in adults and will be manufactured in Ahmedabad, India. The press release highlights that the drug had significant annual sales in the United States, indicating its market potential.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 10, 2024, titled "Zydus receives tentative approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases